Retatrutide in type 2 diabetes mellitus and obesity: an overview - PubMed
4 hours ago
- #Retatrutide
- #Obesity
- #Type 2 Diabetes
- Retatrutide (LY3437943) is a novel triple agonist targeting GCGR, GIPR, and GLP-1R.
- In T2DM patients, it reduces HbA1c by up to 2.16% and fasting glucose by up to 69.1 mg/dL.
- Weight loss up to 16.94% in T2DM patients and up to 26.56% (24.15 kg) in overweight/obese patients.
- Reductions in BMI, waist circumference, and systolic blood pressure observed.
- Liver fat reduced by up to 86% in patients with MASLD.
- Mild-to-moderate gastrointestinal adverse events reported at higher doses.